MX2024005304A - Derivado del acido fenilpropionico sustituido y uso del mismo. - Google Patents

Derivado del acido fenilpropionico sustituido y uso del mismo.

Info

Publication number
MX2024005304A
MX2024005304A MX2024005304A MX2024005304A MX2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A MX 2024005304 A MX2024005304 A MX 2024005304A
Authority
MX
Mexico
Prior art keywords
phenylpropionic acid
derivative
substituted phenylpropionic
provides
substituted
Prior art date
Application number
MX2024005304A
Other languages
English (en)
Spanish (es)
Inventor
Jian Li
Zhen Zhang
Min Liu
Yunfei Li
Liang Tan
Xiaoyan Lin
Jiao Li
Yuqiong Dong
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2024005304A publication Critical patent/MX2024005304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024005304A 2021-11-03 2022-11-03 Derivado del acido fenilpropionico sustituido y uso del mismo. MX2024005304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111293711 2021-11-03
CN202211033065 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (1)

Publication Number Publication Date
MX2024005304A true MX2024005304A (es) 2024-05-17

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005304A MX2024005304A (es) 2021-11-03 2022-11-03 Derivado del acido fenilpropionico sustituido y uso del mismo.

Country Status (10)

Country Link
US (1) US20250042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540183A (cg-RX-API-DMAC7.html)
KR (1) KR20240091010A (cg-RX-API-DMAC7.html)
CN (1) CN118055927A (cg-RX-API-DMAC7.html)
AU (1) AU2022381258A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005304A (cg-RX-API-DMAC7.html)
TW (1) TW202334116A (cg-RX-API-DMAC7.html)
WO (1) WO2023078333A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) * 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
KR20260041098A (ko) * 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) * 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130347A1 (zh) * 2024-12-17 2026-06-25 上海喆邺生物科技有限公司 一种吡咯烷衍生物及其在药物中的用途
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1962596A (zh) * 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US7705177B2 (en) * 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2708706A1 (en) * 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds

Also Published As

Publication number Publication date
EP4428129A1 (en) 2024-09-11
JP2024540183A (ja) 2024-10-31
WO2023078333A1 (zh) 2023-05-11
AU2022381258A1 (en) 2024-05-02
US20250042847A1 (en) 2025-02-06
TW202334116A (zh) 2023-09-01
CN118055927A (zh) 2024-05-17
EP4428129A4 (en) 2025-05-07
WO2023078333A8 (zh) 2023-08-10
KR20240091010A (ko) 2024-06-21
CA3235992A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
PE20151607A1 (es) Formulaciones de compuestos organicos
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo